Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT01300156
Status:
UNKNOWN
Last Update Posted:
2011-02-21
First Post:
2011-02-18
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)
Sponsor:
National Cancer Center, Korea
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-02
Start Date Type:
None
Primary Completion Date:
2013-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2013-12
Completion Date Type:
ESTIMATED
First Submit Date:
2011-02-18
First Submit QC Date:
None
Study First Post Date:
2011-02-21
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-02-18
Last Update Post Date:
2011-02-21
Last Update Post Date Type:
ESTIMATED